Andera Partners co-leads €105 million Series A round for Adcytherix, its first investment from the BioDiscovery 7 fund

EQS-News: Andera Partners / Key word(s): Financing Andera Partners co-leads €105 million Series A round for Adcytherix, its first investment from the BioDiscovery 7 fund 16.10.2025 / 11:05 CET/CEST The issuer is solely responsible for the content of this announcement. Andera Partners co-leads €105 million Series A round for Adcytherix, its first investment from the BioDiscovery 7 fund

• Financing co-led by Andera Partners, Angelini Ventures, Bpifrance and Kurma Partners
• Proceeds to advance lead program ADCX-020 into the clinic, with first IND and CTA filings planned by end 2025
• Funding to advance additionnal innovative ADC programs into the clinic with strategic focus on novel payloads

Paris, France – October 16^th, 2025 – Andera Partners, a leading European private equity player, today announced that it has co-led the Series A financing round of Adcytherix, a biopharmaceutical company developing novel and proprietary antibody drug conjugates (ADC). The transaction represents the first investment from Andera Partners’ new BioDiscovery 7 fund.

The €105 million ($122 million) funding round was co-led by Andera Partners, Angelini Ventures, Bpifrance (as part of both Large Venture and InnoBio investment strategies) and Kurma Partners, followed by Surveyor Capital (a Citadel company), aMoon and existing shareholders Pontifax, DawnBiopharma (a platform controlled by KKR), Pureos Bioventures and RA Capital.

This Series A positions Adcytherix as one of the most promising ADC players, leveraging novel payload classes and an experienced team to bring targeted cancer treatments to patients. The funding will enable the company to advance its lead candidate ADCX-020 into the clinic, with first investigational new drug (IND - US) and clinical trial applications (CTA - EU, UK and Canada) filings planned by end 2025. In parallel, Adcytherix will expand its pipeline of proprietary ADCs using novel payloads.